A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels
Barfield, Robyn M, Kim, Yun Cheol, Chuprakov, Stepan, Zhang, Fangjiu, Bauzon, Maxine, Ogunkoya, Ayodele O., Yeo, Dominick, Hickle, Colin, Pegram, Mark D, Rabuka, David, Drake, Penelope MJournal:
Molecular Cancer Therapeutics
DOI:
10.1158/1535-7163.MCT-20-0190
Date:
July, 2020
Fichier:
PDF, 11.99 MB
2020
File converter
Plus de résultats de recherche
More benefits 
